ORGANIZATIONS REPRESENTED AT THE HEARINGS-Continued Executive Office of the President-Continued Konopka, Arthur F., Acting General Counsel to the Special Consultant to the President for Narcotics and Dangerous Drugs. Perito, Paul L., General Counsel and Assistant Director, Special Action Office for Drug Abuse Prevention, Office of Special Consultant to the President for Narcotics and Dangerous Drugs. Smith, Dr. Carl, Acting Director, Office of Health Affairs, Office of Economic Opportunity. Weber, Arnold R., Associate Director, Office of Management and Budget. Health, Education, and Welfare Department: Besteman, Karst J., Deputy Director, Division of Narcotic Addiction and Drug Abuse, National Institute of Mental Health, National Institutes of Health. Brown, Dr. Bertram S., Director, National Institute of Mental Health. Duncan, Dr. Tommy, Clinical Research Center, Fort Worth, Tex., U.S. Public Health Service. Edwards, Dr. Charles C., Administrator, Food and Drug Administration. Hutt, Peter, General Counsel, Food and Drug Administration. Lacovara, Dr. Dominick, Director, Clinical Research Center, Fort Worth, Lawrence, James, Executive Officer, National Institute of Mental Health, National Institutes of Health, Public Health Service. Richardson, Hon. Elliot L., Secretary. Wilson, Dr. Vernon E., Administrator, Health Services and Mental Health Administration. Zapp, Dr. John S., Deputy Assistant Secretary for Legislation (Health). Justice Department: Burrows, Carl, Assistant Commissioner for Investigation, Immigration and Naturalization Service. Carlson, Norman A., Director, Bureau of Prisons. Coppock, Donald R., Deputy Associate Commissioner for Domestic Control, Immigration and Naturalization Service. Farkas, Gerald M., Executive Assistant to Director, Bureau of Prisons. Garfield, Frederick, Assistant Director for Scientific Support, Bureau of Narcotics, and Dangerous Drugs. Greene, James F., Associate Commissioner for Operations, Immigration and Naturalization Service. Heaney, Richard, Deputy Director, Bureau of Prisons. Ingersoll, John E., Director, Bureau of Narcotics and Dangerous Drugs. Levinson, Dr. Robert B., Mental Health Coordinator, Bureau of Prisons. Maloney, Andrew J., Chief, Narcotics and Racketeering Unit, Southern District of New York. Miller, Donald, Chief Counsel, Bureau of Narcotics and Dangerous Drugs. Seymour, Whitney North, Jr., U.S. Attorney, Southern District of New York. Kemper Insurance Group, Lewis F. Presnall, director of rehabilitation; and manager, Corporate Alcoholism and Other Behavioral Problems Department, National Loss Control Service Corp. (NATLSCO). Louisiana Narcotics Rehabilitation Commission: Alderette, Edward, executive director. Scrignar, Dr. Chester, chairman. Malcolm Bliss Community Mental Health Center: Buis, Jon, NARA aftercare counselor. Davis, Mike. Missouri Division of Mental Health: Knowles, Dr. Raymond R., program director, narcotic addiction treatment program, and chief, alcoholic and drug abuse program. Muse, Alvin. ORGANIZATIONS REPRESENTED AT THE HEARINGS-Continued Narcotic addict rehabilitation agency program, Tulane University: Clark, June, drug addiction research team. Cohen, Dr. Gary, head. Goldsmith, Bernard, systems analyst, drug abuse team. Heath, Dr. Robert G., head, department of social psychiatry. Narcotic Service Council (NASCO)-St. Louis: Harvey, William M., Ph. D., director of psychological services. National Council of Community Mental Health Centers: Levin, Gilbert, Ph. D. Morris, Jonas V., executive director. National Loss Control Service Corp. (NATLSCO), Lewis F. Presnall, manager, corporate alcoholism and other behavioral problems department; and director of rehabilitation, Kemper Insurance Group. New Orleans, La.: Landrieu, Hon. Moon, mayor. Thompson, Dr. Doris, director, city health department. New York City: Finney, Graham S., commissioner, addiction services agency. Lacey, Miss Diane, mayor's office. Lindsay, Hon. John V., mayor. New York State Narcotic Addiction Control Commission: Chambers, Dr. Carl. Hesse, Ray. Jones, Howard, chairman. Parents Foundation Against Drug Abuse: Rembish, Mrs. Helen. Tarantino, Mrs. Mary. Pharmaceutical Manufacturers Association: Adams, Dr. John G., vice president for scientific and professional relations. Cavallito, Dr. Chester J., executive vice president, Ayerst Laboratories. Stetler, C. Joseph, president. Richmond Regional Planning District Commission, M. Miles Matthews, director, council on drug abuse control (CODAC). Rubicon, Inc., Richmond, Va., Edmund Menken, project director. Smith Kline & French Laboratories, Thomas M. Rauch, chairman of the board and president. State Department, Nelson Gross, Senior Adviser to the Secretary of State and Coordinator for International Narcotics Matters. Treasury Department, Eugene T. Rossides, Assistant Secretary (Enforcement, Tariff and Trade Affairs, and Operations. Veterans' Administration: Bronaugh, A. T., Associate General Counsel. Johnson, Donald E., Administrator of Veterans' Affairs. Kaim, Dr. Samuel, Director, Alcohol and Drug Dependence Service. Lee, Dr. Lyndon, Assistant Chief Medical Director for Professional Services. Peckarsky, J. C., Deputy Chief Benefits Director. Virginia Commonwealth University, Richmond, Va.: Brandt, Dr. Warren W., president. Bright, Dr. George M., director, Adolescent Medicine Medical College of Virginia. Harrison, Willard I., M. Sc., director, department of pharmacy services, and project director, methadone treatment program, Medical College of Virginia. Mathis, Dr. James, professor of psychiatry, Medical College of Virginia. Virginia Council on Narcotics and Drug Abuse Control, F. John Kelly, executive director. 66-841 0-72-pt. 1—2 SPECIAL ACTION OFFICE FOR DRUG ABUSE PREVENTION TUESDAY, OCTOBER 26, 1971 HOUSE OF REPRESENTATIVES, SUBCOMMITTEE ON PUBLIC HEALTH AND ENVIRONMENT, Washington, D.C. The subcommittee met at 10 a.m., pursuant to notice, in room 2322, Rayburn House Office Building, Hon. Paul G. Rogers (chairman) presiding. Mr. ROGERS. The subcommittee will come to order, please. We are continuing hearings on legislation to establish a Special Action Office of Drug Abuse Prevention and also looking at public health hospitals. Our first witness this morning is one of our distinguished colleagues, Hon. Jim Wright, a Member of Congress from Texas. Congressman Wright has followed the situation at Fort Worth very closely and we are very anxious to hear from him and the recent report that he is ready to present to the committee. We welcome you to the committee and will be glad to receive your report at this time. If you have anyone you would like to join you at the table we would be glad to have him. STATEMENT OF HON. JIM WRIGHT, A REPRESENTATIVE IN CONGRESS FROM THE STATE OF TEXAS; ACCOMPANIED BY ROBERT G. LAWRENCE, SHERMAN S. WILLSE, SALVATORE J. D'AMICO, AND WILLIAM O. NOLEN, INVESTIGATORS FOR THE PUBLIC WORKS COMMITTEE, SUBCOMMITTEE ON INVESTIGATIONS AND OVERSIGHT Mr. WRIGHT. Thank you very much, Mr. Chairman. There are present in the committee room four members of the professional investigative staff of the Subcommittee on Public Works Investigations and oversight who, at my direction and upon your request, Mr. Chairman, did conduct a study and an investigation in the field following the closing of the Fort Worth facility by the Department of Health, Education, and Welfare on October 8. Those investigators who did extensive traveling and interviewing are Mr. Robert Lawrence, Mr. Sherman Willse, Mr. Sal D'Amico and Mr. William Nolen, all four of whom are here in case the committee should want to inquire of them. I think it is possible for me to summarize their findings in that they made the report directly to me and I then transferred it over to you. Actually, Mr. Chairman, I should say first of all that I am very grateful for the opportunity to come and make this report to this subcommittee. Beyond that I am deeply appreciative of the continuing interest of this subcommittee as has been manifest throughout the year in the future of the Fort Worth facility. Earlier this year I believe it was six members of the subcommittee who visited Fort Worth and held hearings there in the clinical research center. That group included not only the chairman but Mr. Satterfield, Mr. Kyros, Mr. Preyer, and Mr. Symington, and I believe it was the clear consensus of the group who held those hearings that the facility should stay open. Mr. HASTINGS. Excuse me, if the gentleman will yield? In addition to that list, the only Republican, last but not least, I was there, too. Mr. WRIGHT. Mr. Hastings, I was trying to mention those not present in the room today who were there and certainly do recall your being in our city and with great appreciation acknowledge your attentiveness to the importance of this problem. I believe Mr. Roy was also present. Actually it may be a fait accompli that that facility has been transferred to the Bureau of Prisons. I have nothing against the Bureau of Prisons, most certainly. If the facility is no longer to be used by the National Institute of Mental Health or by the Public Health Service, then surely it ought to be used for the most beneficial possible purpose. If it is not to be used as it has been used in the past, then it is far preferable that the Bureau of Prisons should make use of it than that it be dropped from the facilities available to drug patients. But I would like to address myself to the action of the Department of Health, Education, and Welfare in so summarily closing this facility on October 8 at the very time when a House-Senate conference had its future under active consideration. To me that abrupt termination of the facility and the abrupt release of the 94 patients then in the facility constituted an act of almost incredible bad faith with the Congress. That is the first thing I want to say. It was obvious to the Department that the Congress has been interested in this facility. I think it should have been obvious to the Department that the Congress wanted it to remain open. Two years ago a Senate committee conducted similar investigations when the center's closure was being contemplated, and the Department decided in deference to the wishes of the Senate that it be kept open. This year, under the direction and leadership of the distinguished chairman, Mr. Rogers, the House acted on two occasions in overwhelming fashion to express its desire that the facility be continued as a treatment facility for patients committed under the Narcotics Addict Rehabilitation Act of 1966. We did this in an amendment to an appropriation bill-an unusual procedure on the floor of the House. We did it again in the passage by an overwhelming vote of, I think, 370 to four, in passing the resolution which called upon the Department of Health, Education, and Welfare to keep open all Public Health Service hospitals, expressly including those at Fort Worth, Tex., and Lexington, Ky. While this discussion was proceeding in the conference with the Senate on that resolution, on the morning of Friday, October 8, officials in the Department of Health, Education, and Welfare suddenly, abruptly and summarily terminated the facility and |